Methods and compositions relating to expression factors
AssigneeNational Health Research Institutes
InventorsYun-Liang YANG, Chia-Geun Chen, Hsiu-Jung Lo
Life of this patent
Estimating the term…
Abstract
The invention describes an expression factor and methods for inhibiting the growth of cells, for enhancing the activity of a drug, and for inhibiting the virulence of microbes. Methods of screening for expression factor inhibitors are also described. The compositions comprise at least one expression factor inhibitor and may further comprise at least one drug.
Claims24
1-58. (canceled)
A method for enhancing the activity of a drug in a cell, comprising:
- a. contacting the cell with an antisense oligonucleotide that is 7 to 50 nucleotides in length, wherein the antisense oligonucleotide hybridizes to a mid-sporulation element (MSE) sequence comprising the sequence CRCAAA;
- b. inhibiting the expression of at least one efflux pump polynucleotide in the cell;
- and
- b. contacting the cell with at least one drug.
The method claim of 60, wherein the efflux pump expression factor is selected from CaNDT80 and REP1.
The method claim of 63, wherein the efflux pump expression factor is CaNDT80.
The method claim of 59, wherein the antisense oligonucleotide is 12 to 50 nucleotides in length.
The method claim of 59, wherein the antisense oligonucleotide is 20 to 50 nucleotides in length.
The method claim of 59, wherein the antisense oligonucleotide is 20 to 35 nucleotides in length.
A method for enhancing the activity of a drug in a cell, comprising:
- a. contacting the cell with an antisense oligonucleotide that is 7 to 50 nucleotides in length, wherein the antisense oligonucleotide hybridizes to a mid-sporulation element (MSE) sequence comprising the sequence CRCAAA in CaNTD80;
- b. inhibiting the expression of at least one efflux pump polynucleotide selected from CDR1, CDR2, and MDR1;
- and
- c. contacting the cell with at least one drug.
The method claim of 73, wherein the oligonucleotide is 12 to 50 nucleotides in length.
The method claim of 73, wherein the oligonucleotide is 20 to 50 nucleotides in length.
The method claim of 73, wherein the oligonucleotide is 20 to 35 nucleotides in length.
Dependencies are inferred from the claim text.